Objective: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab
antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral …

Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; …

Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-
COV®) reduced viral load, hospitalisation, or death when administered 1: 1 as an …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …

Introduction Data on real-world effectiveness of subcutaneous (SC) casirivimab and
imdevimab (CAS+ IMD) for the treatment of coronavirus disease 2019 (COVID-19) are …

REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has
been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five …

Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to
have the highest mortality rate among the elderly and those with pre-existing medical …